_Cell Therapy

BP2202

First prototype product derived from the novel proprietary allogeneic CAR-T platform using iPS-NKT
Targeting multiple myeloma

BP2202 is a novel allogeneic CAR-T cell therapy, using CAR-transduced iPS cell-derived NKT cells.

NKT cells have multifaceted anti-tumor effects. They not only directly kill tumor cell via NKT cell-specific T cell receptors or NK receptors, but also induce indirect cellular toxicity through the activation of surrounding immune cells such as T cells, dendritic cells and NK cells. This is a feature of NKT cells distinct from other immune cells, especially when used as effector cells constituting CAR-T. Therefore, BP2202 has the potentiality to become a breakthrough, distinguished from other allogeneic CAR-T therapies developed in the past.

In the Phase 1 clinical trial for BP2201, the preliminary safety and early clinical activities of the unmodified iPS-NKT cells was demonstrated. The use of such iPS-NKT cells as an allogeneic CAR-T platform enables the development and deployment of CAR-iPS NKT targeting various antigens across different cancers. The target indication of the first prototype of the platform is multiple myeloma.

The Company has experimentally developed a HER2 targeting CAR-iPSNKT and reported that it exhibited enhanced anti-tumor effects in animal models compared to unmodified iPS-NKT cells, as presented, at SITC 2023 (the Society for Immunotherapy of Cancer Annual Meeting 2023).